[HTML][HTML] A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell …
J Rodrigues-Pereira, JH Kim, M Magallanes… - Journal of Thoracic …, 2011 - Elsevier
Introduction This study compared survival without toxicity in patients with advanced,
nonsquamous non-small cell lung cancer who were treated with first-line pemetrexed …
nonsquamous non-small cell lung cancer who were treated with first-line pemetrexed …
A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung …
J Rodrigues-Pereira, JH Kim… - Journal of thoracic …, 2011 - pubmed.ncbi.nlm.nih.gov
Introduction This study compared survival without toxicity in patients with advanced,
nonsquamous non-small cell lung cancer who were treated with first-line pemetrexed …
nonsquamous non-small cell lung cancer who were treated with first-line pemetrexed …
A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung …
J Rodrigues-Pereira, JH Kim, M Magallanes, DH Lee… - 2011 - ir.ymlib.yonsei.ac.kr
INTRODUCTION: This study compared survival without toxicity in patients with advanced,
nonsquamous non-small cell lung cancer who were treated with first-line pemetrexed …
nonsquamous non-small cell lung cancer who were treated with first-line pemetrexed …
[PDF][PDF] A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small …
J Rodrigues-Pereira, JH Kim, M Magallanes… - Journal of Thoracic …, 2011 - academia.edu
Introduction: This study compared survival without toxicity in patients with advanced,
nonsquamous non-small cell lung cancer who were treated with first-line pemetrexed …
nonsquamous non-small cell lung cancer who were treated with first-line pemetrexed …
A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell …
J Rodrigues-Pereira, JH Kim, M Magallanes… - Journal of Thoracic …, 2011 - jto.org
Introduction This study compared survival without toxicity in patients with advanced,
nonsquamous non-small cell lung cancer who were treated with first-line pemetrexed …
nonsquamous non-small cell lung cancer who were treated with first-line pemetrexed …
A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung …
J Rodrigues-Pereira, JH Kim, M Magallanes… - Journal of Thoracic …, 2011 - europepmc.org
Methods This multicenter, open-label, parallel-group, phase 3 trial comprised patients
randomized (1: 1) to pemetrexed/carboplatin (n= 128) or docetaxel/carboplatin (n= 132) …
randomized (1: 1) to pemetrexed/carboplatin (n= 128) or docetaxel/carboplatin (n= 132) …